Exevir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.

Biosynth – known for supplying the life sciences industry with critical raw materials and services – has announced that Matt Gunnison has been appointed as its new CEO and Kieran Murphy has been appointed as chairman.

Following the stepping down of the previous chair, Gerd Zettlmeissl, MinervaX has appointed Veronica Gambillara Fonck to lead the board of directors.

Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of its new chief executive officer, Darrin T Schellin.

Cluepoints, a data quality oversight and and risk-based quality management software provider, has announced the appointment of Richard Young as its chief strategy officer.

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

Pacira biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff members ‒ Rob Lauzen as chief financial officer (CFO) and Jason Marks as chief legal officer (CLO).

Aseptic packaging company Steriline’s founder Gerardo Fumagalli has ‘passed the torch’ to his children Illaria Fumagalli and Federico Fumagalli, who have been appointed to chief executive officer and chief sales officer, respectively. Gerardo will continue on as chairman of the board of directors.

Pharmaceutical company Eli Lilly has announced the appointment of two senior positions in its public affairs and communications team.

SFA Therapeutics, a clinical-stage biopharmaceutical company, has announced that it has appointed Dr Anada Gubbi as director of biostatistics. Dr Gubbi will be responsible for assisting SFA Therapeutics in effectively developing drug candidates for the treatment of inflammatory diseases.